Creutzfeldt–Jakob disease
Generated by GPT-5-miniExpansion Funnel Raw 1 → Dedup 0 → NER 0 → Enqueued 0
| Creutzfeldt–Jakob disease | |
|---|---|
| Name | Creutzfeldt–Jakob disease |
| Specialty | Neurology, Infectious disease, Pathology |
| Symptoms | Rapid cognitive decline, myoclonus, ataxia |
| Onset | Variable (sporadic, hereditary, iatrogenic, variant) |
| Duration | Weeks to months (typically) |
| Causes | Misfolded prion protein (PrP^Sc) |
| Diagnosis | EEG, MRI, CSF tests, PRNP genotyping, neuropathology |
| Treatment | Supportive care, symptom control |
| Frequency | ~1–2 per million per year (sporadic) |
Creutzfeldt–Jakob disease is a rare, rapidly progressive neurodegenerative disorder caused by transmissible misfolded prion proteins. It presents with rapidly progressive dementia, myoclonus, cerebellar dysfunction and akinetic mutism, and is universally fatal within months to a few years in most cases. Clinical recognition, laboratory support and neuropathological confirmation guide management, infection control and surveillance.
signs and symptoms
The typical presentation includes rapidly progressive dementia with early cognitive impairment, behavioral change and memory loss associated with myoclonus, gait disturbance and visual symptoms; patients often develop akinetic mutism and widespread neurological decline. Prominent features are cognitive decline, cerebellar ataxia, extrapyramidal signs and cortical blindness, with neurological progression leading to stupor, coma and death. In some familial forms onset may be earlier with predominant cerebellar or psychiatric features, while iatrogenic and variant forms can present with prominent sensory symptoms, insomnia or peripheral neuropathy.
causes and pathophysiology
The disease is caused by accumulation of an abnormal, protease‑resistant isoform of the prion protein (PrP^Sc) that arises from misfolding of the normal cellular prion protein (PrP^C), encoded by the PRNP gene on chromosome 20. Pathophysiology involves templated conformational change, neuronal loss, spongiform change and gliosis; transmissibility occurs via contaminated neurosurgical instruments, dura mater grafts, pituitary-derived growth hormone and dietary exposure in variant cases. Molecular strain variation, codon 129 methionine/valine polymorphism and PRNP mutations influence incubation period, phenotype and tissue tropism.
diagnosis
Diagnosis relies on clinical assessment, supportive investigations and neuropathology when available. Electroencephalography may show periodic sharp wave complexes; brain magnetic resonance imaging often demonstrates hyperintensity in the caudate, putamen or cortical ribbon on diffusion‑weighted imaging. Cerebrospinal fluid assays including 14‑3‑3 protein, total tau and real‑time quaking‑induced conversion provide biochemical support, while PRNP sequencing identifies pathogenic variants; definitive diagnosis requires neuropathological examination demonstrating prion protein deposition and spongiform change. Infection control measures and public health notification are integral when iatrogenic or variant forms are suspected.
classification and variants
Clinical and etiological classification includes sporadic, familial (genetic), iatrogenic and variant forms. Sporadic cases are the most common; familial cases are associated with PRNP mutations such as E200K, D178N and other missense variants; iatrogenic transmission has been documented via contaminated surgical instruments, dura mater, and human pituitary‑derived preparations; variant cases are linked to dietary exposure to bovine spongiform encephalopathy in affected regions. Subtyping by molecular profile—based on PrP^Sc type and codon 129 genotype—correlates with clinicopathological phenotypes and informs surveillance classification.
treatment and management
There is no cure; management is supportive and focuses on symptom control, palliative care and prevention of complications. Multidisciplinary care addresses pain, myoclonus with anticonvulsants, spasticity, nutrition, infection prevention and advanced care planning; experimental therapies targeting prion replication, clearance or neuroprotection have been investigated in clinical trials without proven disease‑modifying benefit to date. Rigorous decontamination protocols, sterilization standards for instruments and exclusion of implicated blood or tissue products are essential to prevent iatrogenic transmission, and genetic counseling is recommended for families with PRNP mutations.
epidemiology and public health
Incidence of sporadic cases is approximately one to two per million population per year worldwide, with geographic and temporal surveillance coordinated by national public health agencies and international organizations. Variant cases declined following control measures in agriculture and the food chain; iatrogenic clusters prompted changes in surgical practice, tissue handling and blood product policies. Surveillance, reporting, donor deferral, instrument decontamination guidelines and public health communication aim to minimize transmission risk and to identify emerging clusters or novel prion strains.